Gynesonics, a Redwood City, CA-based healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, raised $42.5M in funding.
The round, which brought, since an initial investment in April 2023, the total amount to $67.2M, was led by Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital, with new investments coming from MVM Partners as well as other healthcare investors.
The company intends to use the funds to expand operations and its business reach.
Led by Skip Baldino, President and CEO, Gynesonics is committed to developing and delivering minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Its flagship product, the Sonata System®, is an FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, a medical condition affecting roughly 80% of adult women. Prior to the Sonata System, fibroid removal was limited to invasive medical procedures, like a hysterectomy, which carries greater risk and significantly more recovery time.
Sonata’s innovative technology removes fibroids in a roughly 45-minute outpatient procedure with most patients resuming regular activity the next day.
The Sonata System is CE-marked and is approved for sale in the European Union, the United Kingdom, Switzerland, and the United States.